In 1953 was created Andera Partners, which is appeared as VC. The fund was located in Europe if to be more exact in France. The main department of described VC is located in the Paris.
We also calculated 28 valuable employees in our database.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Andera Partners, startups are often financed by Neomed Management, Omnes Capital, Ysios Capital. The meaningful sponsors for the fund in investment in the same round are Omnes Capital, Idinvest Partners, Gimv. In the next rounds fund is usually obtained by Neomed Management, VI Partners AG, Omnes Capital.
The real fund results show that this VC is 20 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Andera Partners performs on 0 percentage points more the average number of lead investments. The top amount of exits for fund were in 2015. The fund is constantly included in 7-12 investment rounds annually. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the various public portfolio startups of the fund, we may underline Vivoryon Therapeutics, AM Pharma, Arvelle Therapeutics The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Manufacturing, Health Diagnostics.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Qovoltis | 03 Oct 2024 | Arcueil, Ile-de-France, France | |||
Skysun | $20M | 10 Sep 2024 | Brabant Wallon, Walloon Brabant, Belgium | ||
SciRhom | $74M | 09 Jul 2024 | Martinsried, Bayern, Germany | ||
Grey Wolf Therapeutics | $50M | 23 May 2024 | Oxford, England, United Kingdom | ||
MMI | $110M | 21 Feb 2024 | Italy, Tuscany, Italy | ||
ENYO Pharma | $46M | 03 Jan 2024 | Lyon, Auvergne-Rhône-Alpes, France | ||
Nouscom | $79M | 14 Nov 2023 | Basel, Basel-City, Switzerland | ||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Evommune | $50M | 26 Apr 2023 | California, United States |
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Qovoltis | 03 Oct 2024 | Arcueil, Ile-de-France, France | |||
Skysun | $20M | 10 Sep 2024 | Brabant Wallon, Walloon Brabant, Belgium | ||
SciRhom | $74M | 09 Jul 2024 | Martinsried, Bayern, Germany | ||
Grey Wolf Therapeutics | $50M | 23 May 2024 | Oxford, England, United Kingdom | ||
MMI | $110M | 21 Feb 2024 | Italy, Tuscany, Italy | ||
ENYO Pharma | $46M | 03 Jan 2024 | Lyon, Auvergne-Rhône-Alpes, France | ||
Nouscom | $79M | 14 Nov 2023 | Basel, Basel-City, Switzerland | ||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Evommune | $50M | 26 Apr 2023 | California, United States |
